Mylan (MYL) announced the U.S. launch of Dalfampridine Extended-Release Tablets, 10 mg, the authorized generic version of Acorda’s (ACOR) Ampyra, which is indicated to improve walking in adult patients with multiple sclerosis. The launch comes after the United States Court of Appeals for the Federal Circuit upheld the United States District Court for the District of Delaware’s decision to invalidate four Ampyra patents: U.S. Patent Nos. 8,663,685, 8,007,826, 8,440,703, and 8,354,437. Acorda’s U.S. Patent No. 5,540,938, previously upheld by the District Court, expired on July 30, 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.